Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2

Technology appraisal guidance
Reference number: TA257
Published: 27 June 2012

TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appendix A - matrix of stakeholders

TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appendix A - matrix of stakeholders

TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appendix A - matrix of stakeholders
29 June 2015
(97.81 Kb 28 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 25 June 2015